UCB UCBJF Stock
UCB Price Chart
UCB UCBJF Financial and Trading Overview
| UCB stock price | 230.5 USD |
| Previous Close | 236.66 USD |
| Open | 230.5 USD |
| Bid | 220.9 USD x 100 |
| Ask | 238.9 USD x 100 |
| Day's Range | 230.5 - 230.5 USD |
| 52 Week Range | 219.6 - 345.39 USD |
| Volume | 3 USD |
| Avg. Volume | 498 USD |
| Market Cap | 43.95B USD |
| Beta (5Y Monthly) | 0.192 |
| PE Ratio (TTM) | 17.462122 |
| EPS (TTM) | 13.2 USD |
| Forward Dividend & Yield | 1.7 (0.72%) |
| Ex-Dividend Date | May 4, 2026 |
| 1y Target Est | N/A |
UCBJF Valuation Measures
| Enterprise Value | 47.17B USD |
| Trailing P/E | 17.462122 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 1.09 |
| Price/Sales (ttm) | 5.155763 |
| Price/Book (mrq) | 3.54928 |
| Enterprise Value/Revenue | 5.534 |
| Enterprise Value/EBITDA | 15.033 |
Trading Information
UCB Stock Price History
| Beta (5Y Monthly) | 0.192 |
| 52-Week Change | -21.011% |
| S&P500 52-Week Change | 17.38% |
| 52 Week High | 345.39 USD |
| 52 Week Low | 219.6 USD |
| 50-Day Moving Average | 251.89 USD |
| 200-Day Moving Average | 287.01 USD |
UCBJF Share Statistics
| Avg. Volume (3 month) | 498 USD |
| Avg. Daily Volume (10-Days) | 120 USD |
| Shares Outstanding | 190.66M |
| Float | 120.16M |
| Short Ratio | N/A |
| % Held by Insiders | 36.27% |
| % Held by Institutions | 39.48% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.45 |
| Trailing Annual Dividend Yield | 0.61% |
| 5 Year Average Dividend Yield | 98.00% |
| Payout Ratio | 0.12810001 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 25.73% |
| Operating Margin (ttm) | 33.32% |
| Gross Margin | 76.21% |
| EBITDA Margin | 36.81% |
Management Effectiveness
| Return on Assets (ttm) | 8.30% |
| Return on Equity (ttm) | 20.56% |
Income Statement
| Revenue (ttm) | 8.52B USD |
| Revenue Per Share (ttm) | 44.77 USD |
| Quarterly Revenue Growth (yoy) | 22.50% |
| Gross Profit (ttm) | 6.5B USD |
| EBITDA | 3.14B USD |
| Net Income Avi to Common (ttm) | 2.19B USD |
| Diluted EPS (ttm) | 13.2 |
| Quarterly Earnings Growth (yoy) | 133.90% |
Balance Sheet
| Total Cash (mrq) | 766M USD |
| Total Cash Per Share (mrq) | 4.02 USD |
| Total Debt (mrq) | 3.59B USD |
| Total Debt/Equity (mrq) | 30.79 USD |
| Current Ratio (mrq) | 1.203 |
| Book Value Per Share (mrq) | 64.94275 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.95B USD |
| Levered Free Cash Flow (ttm) | 970.5M USD |
Profile of UCB
| Country | United States |
| State | N/A |
| City | Brussels |
| Address | Allée de la Recherche, 60 |
| ZIP | 1070 |
| Phone | 32 2 559 99 99 |
| Website | https://www.ucb.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9000 |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Q&A For UCB Stock
What is a current UCBJF stock price?
UCB UCBJF stock price today per share is 230.5 USD.
How to purchase UCB stock?
You can buy UCBJF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for UCB?
The stock symbol or ticker of UCB is UCBJF.
Which industry does the UCB company belong to?
The UCB industry is Biotechnology.
How many shares does UCB have in circulation?
The max supply of UCB shares is 190.66M.
What is UCB Price to Earnings Ratio (PE Ratio)?
UCB PE Ratio is 17.46212200 now.
What was UCB earnings per share over the trailing 12 months (TTM)?
UCB EPS is 13.2 USD over the trailing 12 months.
Which sector does the UCB company belong to?
The UCB sector is Healthcare.
